title: Current status of therapeutic apheresis in rheumatoid arthritis.
abstract: Evidence developed over the years has suggested that lymphocyte depletion and removal of plasma factors can ameliorate rheumatoid arthritis. In our studies of 40 patients, a subset of patients that respond best to 20 therapeutic lymphoplasmapheresis over 11 weeks has emerged. These are functional Class III patients with seropositive, erosive progressive disease who have little deformity. They must be on long-acting agents or cytotoxic drugs during pheresis to prevent antibody rebound. Other studies have since confirmed our work. The major side effects of pheresis are elucidated. Technologic developments will enable selective pheresis procedures to be in widespread use within a few years.
mesh_terms: D001172:Arthritis, Rheumatoid / Q000628:therapy*; D006801:Humans; D007937:Leukapheresis; D010956:Plasmapheresis